Emoglobina glicata: la regina indiscussa?
Il Diabete · 07.05.2026 · 38 (1)
DOI: 10.30682/ildia2601a ↗Kurz gefasst
Fachartikel in der Zeitschrift Il Diabete, online erschienen am 07.05.2026. Verfasst von Gabriele Giachetti und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Glycated haemoglobin (HbA1c) is still the reference biomarker in diabetes mellitus for the management of glucose control and the assessment of the risk of organ damage due to hyperglycemia. This brief review deals with the current clinical use, the clinical advantages and the main limitations, both analytic and biologic, of HbA1c, also in comparison with other, more recent biomarkers of glucose control. The conclusions highlight that the pivotal role of HbA1c is justified in most clinical settings, but also that the HbA1c limitations should be recognized, in order to maximize the benefits its use can supply.
Zitieren
APA
Giachetti, G., Molinaroli, E., & Bonadonna, R. C. (2026). Emoglobina glicata: la regina indiscussa?. Il Diabete, 38(1). https://doi.org/10.30682/ildia2601a
Vancouver
Giachetti G, Molinaroli E, Bonadonna RC. Emoglobina glicata: la regina indiscussa?. Il Diabete. 2026;38(1). doi:10.30682/ildia2601a
BibTeX
@article{Giachetti2026,
author = {Giachetti, Gabriele and Molinaroli, Elisa and Bonadonna, Riccardo C.},
title = {Emoglobina glicata: la regina indiscussa?},
journal = {Il Diabete},
year = {2026},
volume = {38},
number = {1},
doi = {10.30682/ildia2601a}
}
EUVIMED